Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

Phase 2 Completed 28 enrolled VA Office of Research and Development

NaSingle-groupOpen-labelTreatment

Summary

This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.

Timeline

Start: 2018-07-01
Primary completion: 2024-03-31
Completion: 2024-03-31

Publications

Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 1;19(1):291. doi: 10.1186/s12885-019-5496-5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abiraterone acetate	Small molecule	—	—
Subject	Apalutamide	Small molecule	—	—
Subject	Leuprolide	Other / unclassified	—	—

Indications

No indication recorded.